AXLA Key Statistics, Chart & Performance
The current stock price of AXLA is 4.58 USD. In the past month the price decreased by -33.72%. In the past year, price decreased by -80.3%.
AXLA Latest News, Press Relases and Analysis
AXLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.85B | ||
| AMGN | AMGEN INC | 15.43 | 181.73B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 107.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 78.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.29 | 60.05B | ||
| INSM | INSMED INC | N/A | 45.09B | ||
| NTRA | NATERA INC | N/A | 32.33B | ||
| BIIB | BIOGEN INC | 10.62 | 26.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About AXLA
Company Profile
Axcella Health Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 11 full-time employees. The company went IPO on 2019-05-09. Axcella Health Inc. is a clinical-stage biotechnology company. The firm is focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with simultaneously impacting multiple biological pathways. Its pipeline includes lead therapeutic candidates for the treatment of Long COVID (also known as Post-COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC)) associated fatigue, and the treatment of non-alcoholic steatohepatitis (NASH). AXA1665 is a product candidate for the reduction in risk of Overt Hepatic Encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. AXA1125 is also being developed as a product candidate for the treatment of Long COVID. AXA1125 is an oral product candidate for the treatment of NASH. AXA1125 is an oral product candidate that contains six amino acids and derivatives.
Company Info
AXCELLA HEALTH INC
840 Memorial Dr
Cambridge MASSACHUSETTS 02139 US
CEO: William R. Hinshaw
Employees: 11
Phone: 16178680949.0
AXCELLA HEALTH INC / AXLA FAQ
What does AXCELLA HEALTH INC do?
Axcella Health Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 11 full-time employees. The company went IPO on 2019-05-09. Axcella Health Inc. is a clinical-stage biotechnology company. The firm is focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with simultaneously impacting multiple biological pathways. Its pipeline includes lead therapeutic candidates for the treatment of Long COVID (also known as Post-COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC)) associated fatigue, and the treatment of non-alcoholic steatohepatitis (NASH). AXA1665 is a product candidate for the reduction in risk of Overt Hepatic Encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. AXA1125 is also being developed as a product candidate for the treatment of Long COVID. AXA1125 is an oral product candidate for the treatment of NASH. AXA1125 is an oral product candidate that contains six amino acids and derivatives.
What is the stock price of AXCELLA HEALTH INC today?
The current stock price of AXLA is 4.58 USD. The price decreased by -16.42% in the last trading session.
Does AXCELLA HEALTH INC pay dividends?
AXLA does not pay a dividend.
What is the ChartMill rating of AXCELLA HEALTH INC stock?
AXLA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Would investing in AXCELLA HEALTH INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AXLA.
AXLA Technical Analysis
AXLA Financial Highlights
Over the last trailing twelve months AXLA reported a non-GAAP Earnings per Share(EPS) of -19.25. The EPS increased by 42.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -518.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AXLA Forecast & Estimates
8 analysts have analysed AXLA and the average price target is 15870.1 USD. This implies a price increase of 346408.73% is expected in the next year compared to the current price of 4.58.